Zydus LifesCiences said on Monday that it has received approval to marketing a common antifungal drug from the US Health Regulator USFDA to treat dandruff, fungal infection and other skin conditions.
The company has obtained final approval for the construction of ketoconzole shampoo, 2 PCs from the US Food and Drug Administration, it has been said in a statement.
Ketoconazole shampoo is an antifungal drug used to treat dandruff, fungal infection and other skin conditions.
The product will be produced at Changodar, Ahmedabad at the topical manufacturing site of the Zidus group.
IQVIA MAT, according to January 2025 data, Ketoconzole Shampoo had an annual sales of $ 68.89 MN in the US.
Zydus Lifescienes shares were trading up 0.22% at Rs 903.10 on BSE.
Read more on business by NDTV benefits. (Tagstotranslet) zydus lifescienes ltd. (T) PTI
